Tevogen Bio (TVGN) Expected to Announce Earnings on Thursday

Tevogen Bio (NASDAQ:TVGN) is expected to announce its results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($2.5350) per share for the quarter.

Tevogen Bio (NASDAQ:TVGN) last announced its quarterly earnings data on Friday, May 15th. The company reported ($1.61) earnings per share for the quarter, beating the consensus estimate of ($2.64) by $1.03.

Tevogen Bio Stock Performance

TVGN opened at $6.85 on Thursday. The business’s 50-day simple moving average is $7.26 and its 200 day simple moving average is $8.78. Tevogen Bio has a 52-week low of $3.64 and a 52-week high of $55.00. The firm has a market capitalization of $28.90 million, a PE ratio of -1.49 and a beta of 0.18.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research report on Friday, July 17th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $100.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TVGN. Deutsche Bank AG raised its stake in Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after acquiring an additional 130,738 shares during the period. Goldman Sachs Group Inc. boosted its position in Tevogen Bio by 126.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after purchasing an additional 152,572 shares during the period. Finally, Bridgeway Capital Management LLC boosted its position in Tevogen Bio by 66.7% during the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after purchasing an additional 33,000 shares during the period.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.